Literature DB >> 21658121

Low incidence of cardiovascular events in Japanese patients with Type 2 diabetes in primary care settings: a prospective cohort study (JDDM 20).

H Yokoyama1, M Matsushima, K Kawai, K Hirao, M Oishi, H Sugimoto, H Takeda, M Minami, M Kobayashi, H Sone.   

Abstract

AIMS: To investigate whether a reduced incidence of cardiovascular disease in Type 2 diabetes can be achieved in a newly recruited cohort following the recently advanced concept of multifactorial treatment and followed in primary care settings as compared with earlier cohorts.
METHODS: A prospective study was performed in primary care settings at multiple clinics nationwide in the Japan Diabetes Clinical Data Management (JDDM) study group. Subjects were 2984 patients with Type 2 diabetes without prevalent cardiovascular disease. The main outcome measure was the first event of non-fatal or fatal coronary heart disease, ischaemic stroke or peripheral artery disease, and the incidence was compared with other representative cohorts.
RESULTS: There were 90 cardiovascular events over 10,827 person-years of follow-up with a dropout rate of 6%. The incidences (per 1000 person-years, 95% confidence interval) of composite, coronary heart disease, ischaemic stroke and peripheral artery disease in the JDDM study were 8.3 (6.6-10.0), 4.4 (3.2-5.6), 3.1 (2.1-4.2), and 0.7 (0.2-1.2), respectively. Each incidence was lowest in the JDDM study compared with other cohorts (P < 0.01 vs. each cohort). In the JDDM study, significant variables predictive of the occurrence of a cardiovascular event were age, duration of diabetes, HbA(1c), HDL cholesterol and urinary albumin.
CONCLUSION: The novel finding of low cardiovascular disease occurrence in this study may be conferred by the feasibility at primary care settings for providing patients with Type 2 diabetes with favourable control of blood glucose, blood pressure and lipids, coupled with unique ethnicity/country factors.
© 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21658121     DOI: 10.1111/j.1464-5491.2011.03347.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  16 in total

1.  ApoE isoforms, treatment of diabetes and the risk of coronary heart disease.

Authors:  Hideki Ehara; Ritsuko Yamamoto-Honda; Hiroji Kitazato; Yoshihiko Takahashi; Shoji Kawazu; Yasuo Akanuma; Mitsuhiko Noda
Journal:  World J Diabetes       Date:  2012-03-15

2.  Chronic kidney disease categories and renal-cardiovascular outcomes in type 2 diabetes without prevalent cardiovascular disease: a prospective cohort study (JDDM25).

Authors:  H Yokoyama; S Araki; M Haneda; M Matsushima; K Kawai; K Hirao; M Oishi; K Sugimoto; H Sone; H Maegawa; A Kashiwagi
Journal:  Diabetologia       Date:  2012-04-04       Impact factor: 10.122

3.  Comparison of HOMA-IR, HOMA-β% and disposition index between US white men and Japanese men in Japan: the ERA JUMP study.

Authors:  Vasudha Ahuja; Takashi Kadowaki; Rhobert W Evans; Aya Kadota; Tomonori Okamura; Samar R El Khoudary; Akira Fujiyoshi; Emma J M Barinas-Mitchell; Takashi Hisamatsu; Abhishek Vishnu; Katsuyuki Miura; Hiroshi Maegawa; Aiman El-Saed; Atsunori Kashiwagi; Lewis H Kuller; Hirotsugu Ueshima; Akira Sekikawa
Journal:  Diabetologia       Date:  2014-10-15       Impact factor: 10.122

4.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

5.  Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes.

Authors:  Takashi Wada; Masakazu Haneda; Kengo Furuichi; Tetsuya Babazono; Hiroki Yokoyama; Kunitoshi Iseki; Shin-ichi Araki; Toshiharu Ninomiya; Shigeko Hara; Yoshiki Suzuki; Masayuki Iwano; Eiji Kusano; Tatsumi Moriya; Hiroaki Satoh; Hiroyuki Nakamura; Miho Shimizu; Tadashi Toyama; Akinori Hara; Hirofumi Makino
Journal:  Clin Exp Nephrol       Date:  2013-10-17       Impact factor: 2.801

6.  Time to consider an Asian guideline for management of dyslipidemia?

Authors:  Koutaro Yokote; Yasushi Saito
Journal:  J Diabetes Investig       Date:  2012-06-06       Impact factor: 4.232

Review 7.  Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus.

Authors:  Kazuya Fujihara; Hirohito Sone
Journal:  Ann Vasc Dis       Date:  2018-03-25

8.  Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33).

Authors:  Hiroki Yokoyama; Koichi Hirao; Kohei Yamaguchi; Mariko Oishi; Gendai Lee; Noriharu Yagi; Hiroshi Takamura; Atsunori Kashiwagi
Journal:  Jpn Clin Med       Date:  2014-09-17

9.  Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.

Authors:  Eiichi Araki; Yukiko Onishi; Michiko Asano; Hyosung Kim; Ella Ekholm; Eva Johnsson; Toshitaka Yajima
Journal:  J Diabetes Investig       Date:  2016-01-22       Impact factor: 4.232

10.  Relationship Between Glycated Hemoglobin and Stroke Risk: A Systematic Review and Meta-Analysis.

Authors:  John Peter Mitsios; Elif Ilhan Ekinci; Gregory Peter Mitsios; Leonid Churilov; Vincent Thijs
Journal:  J Am Heart Assoc       Date:  2018-05-17       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.